Tumor Cell Or Cancer Cell Patents (Class 435/7.23)
  • Patent number: 11009507
    Abstract: Provided herein are methods and compositions for detecting and characterizing estrogen receptor-negative solid tumor cancers.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: May 18, 2021
    Assignee: University of New England
    Inventor: Srinidi Mohan
  • Patent number: 10975442
    Abstract: In one aspect, provided herein is a method comprising: (a) (i) determining cytolytic activity in a tumor from the subject; and/or (ii) determining genetic alterations associated with cytolytic activity in the tumor; and (b) administering an immunotherapeutic agent to the subject if (i) cytolytic activity is detected in the tumor and/or (ii) a genetic alteration associated with induction of cytolytic activity, tumor resistance to cytolytic activity and/or suppression of cytolytic activity is detected in the tumor.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: April 13, 2021
    Assignees: Massachusetts Institute of Technology, The General Hospital Corporation
    Inventors: Nir Hacohen, Michael S. Rooney
  • Patent number: 10969380
    Abstract: The present inventors show that cannibal cells can undergo senescence after entosis in vivo and that the tumor suppressive protein p53 act as a repressor of this phenomenon. They therefore propose new tools to study the molecular pathways involved in the cannibalism process, for example by measuring the expression levels of p53 or splice variants thereof (such as ?133TP53, TP53?, TP53? or ?40TP53), the release of extracellular ATP or purinergic P2Y2 receptor activity. The present inventors also demonstrated that the detection of senescent cannibal cells in breast adenocarcinoma obtained from patients treated with neo-adjuvant therapy positively correlates with good patient's response to treatment. Altogether, these results provide the first evidence that detection of cellular cannibalism and senescence simultaneously in tumors helps for the diagnosis of disease outcomes and for the prediction of treatment efficiency against cancer diseases.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: April 6, 2021
    Assignee: Institut Gustave Roussy
    Inventors: Jean-Luc Perfettini, Guido Kroemer, Eric Deutsch
  • Patent number: 10969392
    Abstract: A method of detecting cell membrane expression of an MHC molecule in a subject, a method of treating cancer in a subject with an immunotherapeutic agent, and an MHC complex are provided. The method of detecting cell membrane expression of an MHC molecule includes obtaining a tumor cell sample from a subject, and detecting cell membrane expression of the MHC molecule by contacting the tumor cell sample with an antibody targeting the MHC molecule and detecting binding between the MHC molecule and the antibody. The method of treating cancer in a subject with an immunotherapeutic agent includes detecting cell membrane expression of an MHC molecule in the subject and administering a therapeutically effective amount of the immunotherapeutic agent if the level of cell membrane expression of the MHC molecule exceeds a predetermined standard. The complex includes a tumor cell in complex with an antibody or an antigen-binding portion thereof.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: April 6, 2021
    Assignee: Vanderbilt University
    Inventors: Justin M. Balko, Douglas B. Johnson, Violeta Sanchez de Delgado, Melinda Sanders
  • Patent number: 10962545
    Abstract: The present invention relates to methods, kits, and compositions for detecting and/or diagnosing metastatic potential of cancer cells or for evaluating prognosis in a patient with cancer by detection of the protein expression level of an HLA class I molecule and/or the copy number variation of a polynucleotide encoding the HLA class I molecule. The present invention also relates to the use of the protein expression level of an HLA class I molecule and/or the copy number variation of a polynucleotide encoding the HLA class I molecule as a prognosis biomarker and metastasis predictive biomarker of cancer.
    Type: Grant
    Filed: August 13, 2018
    Date of Patent: March 30, 2021
    Assignees: BGI TECH SOLUTIONS CO., LTD, BEIJING INSTITUTE FOR CANCER RESEARCH
    Inventors: Rui Xing, Youyong Lu, Zhibo Gao, Wenmei Li, Jiantao Cui, Lin Li, Longyun Chen
  • Patent number: 10953079
    Abstract: Compositions comprising a nucleic acid molecule that encodes TB esat-6 proteins are disclosed. Methods of inducing an immune response against TB an individual are disclosed. Method of treating an individual who has been diagnosed with TB are disclosed. Method of preventing TB infection in an individual are disclosed.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: March 23, 2021
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David B. Weiner, Daniel Villarreal
  • Patent number: 10952415
    Abstract: The present disclosure, in part, is directed to a mammalian prostate cancer cell line comprising at least one or a set of primary mammalian epithelial cells which have been infected with a retroviral vector carrying an oncogene selected from the group consisting of c-Myc, Ha-Ras, NeuT, c-Src and combinations thereof and in which said gene is expressed.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: March 23, 2021
    Inventor: Richard G. Pestell
  • Patent number: 10928398
    Abstract: The present invention relates to kits and methods for performing dual-staining immunohistochemistry (IHC) for the detection of specific cell populations in tissue samples containing heterogeneous populations of cells, which can be observed by a light microscope for co-localization of distinct pigments. The method includes providing a tissue sample comprising fixed cells; exposing the sample to first and second ligands that recognize different marker proteins found at the same cellular location, thereby forming a ligand-labeled sample; exposing the ligand-labeled sample to first and second labeling reagents, the first labeling reagent binding to the first ligand and the second labeling reagent binding to the second ligand, the first and second labeling reagents each forming distinct pigments; and identifying the number of cells that display only one particular pigment, or more than one pigment, by the different coloration of the cellular location labeled by the distinct pigment.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: February 23, 2021
    Assignee: CORNELL UNIVERSITY
    Inventor: Scott A. Ely
  • Patent number: 10895573
    Abstract: Among others, the present invention provides apparatus for interacting with a biological subject to detect circulating tumor cells therein, comprising one device for sending a signal to the biological subject and optionally receiving a response to the signal from the biological entity.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: January 19, 2021
    Assignee: AnPac Bio-Medical Science Co., Ltd.
    Inventors: Chris C. Yu, Xuedong Du, He Yu
  • Patent number: 10889543
    Abstract: The present invention relates to novel small molecule modulators of Nav1.6 channels of the general formulae (I), (II), (III) and (IV), and the uses thereof.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: January 12, 2021
    Assignee: The Board of Regents of The University of Texas System
    Inventors: Fernanda Laezza, Jia Zhou, Zhiqing Liu, Syed Ali
  • Patent number: 10889625
    Abstract: Methods for treating and preventing neurodegenerative disease, neurological injury, including stroke, via administration of Transient receptor potential M2 (TRPM2)-inhibitors. The inhibitors may be administered in conjunction with another therapeutic agent or therapeutic regimen. The peptides may be administered to a human male. The peptides may be administered within eight hours of a neurological injury, such as a stroke.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: January 12, 2021
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventor: Paco S. Herson
  • Patent number: 10883101
    Abstract: The present disclosure provides a HTP microbial genomic engineering platform that is computationally driven and integrates molecular biology, automation, and advanced machine learning protocols. This integrative platform utilizes a suite of HTP molecular tool sets to create HTP genetic design libraries, which are derived from, inter alia, scientific insight and iterative pattern recognition. The HTP genomic engineering platform described herein is microbial strain host agnostic and therefore can be implemented across taxa. Furthermore, the disclosed platform can be implemented to modulate or improve any microbial host parameter of interest.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: January 5, 2021
    Assignee: Zymergen Inc.
    Inventors: Zach Serber, Erik Jedediah Dean, Shawn Manchester, Katherine Gora, Michael Flashman, Erin Shellman, Aaron Kimball, Shawn Szyjka, Barbara Frewen, Thomas Treynor, Kenneth S. Bruno
  • Patent number: 10874610
    Abstract: This invention is related to use of exosomes for biomarker analysis for early detecting and characterizing of disease progression of cancer. Further, the invention provides bioengineered exosomes for use in methods of targeting and treating cancer.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: December 29, 2020
    Assignees: Northwestern University, Case Western Reserve University
    Inventors: Huiping Liu, Erika K. Ramos, Nurmaa K. Dashzeveg, Golam Kibria
  • Patent number: 10878936
    Abstract: BioMEMS/NEMS appliance biologically monitors an individual, using biosensors to detect cellular components. Data is simulated or analyzed using systems-biology software, which provides diagnostic or therapeutic guidance.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: December 29, 2020
    Inventor: Dennis Sunga Fernandez
  • Patent number: 10864251
    Abstract: The present invention provides a peptide derived from the extracellular domain of syndecan-1 that inhibits angiogenesis.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: December 15, 2020
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Alan C. Rapraeger, DeannaLee M. Beauvais
  • Patent number: 10858409
    Abstract: The present invention provides an isolated or recombinant protein consisting of the amino acid sequence according to SEQ ID NO: 3 or SEQ ID: NO: 4 and its use in the prevention or treatment of an inflammatory condition.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: December 8, 2020
    Assignee: IMMUNE REGULATION LIMITED
    Inventors: Valerie Mary Corrigall, Gabriel Stavros Panayi
  • Patent number: 10852302
    Abstract: A novel convenient method for evaluating the function of a phagocyte is provided. The method assays sCD14-ST, which is a humoral factor specifically produced in phagocytosis by the phagocyte and which is stable enough for use in an assay. Also provided is a method for detecting diseases associated with the phagocytosis by the phagocyte.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: December 1, 2020
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventor: Katsuki Naito
  • Patent number: 10823736
    Abstract: A method, system and computer-readable medium for assessing a disease condition of a cancer of a subject, including: receiving a blood sample from the subject; isolating a plurality of circulating tumor cells (CTCs) from the blood sample; measuring at least one of cell or cell nucleus sizes of each of the plurality of CTCs; determining a measured CTC size distribution of the plurality of CTCs based on the measuring; comparing the measured CTC size distribution to a reference CTC size distribution using a computer; and assigning the disease condition of the cancer of the subject based on the comparing.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: November 3, 2020
    Assignees: The Regents of the University of California, Cedars-Sinai Medical Center
    Inventors: Hsian-Rong Tseng, Jiaoti Huang, Edwin M. Posadas, Jiefu Chen, Hao Ho, Zunfu Ke, Ker-Chau Li, Yi-Tsung Lu, Jake Lichterman, Min Song, Leland W. K. Chung
  • Patent number: 10809263
    Abstract: Provided are an autoantibody specifically binding to an exosomal protein EIF3A (Eukaryotic translation initiation factor 3 subunit A) or a fragment including an antigen-binding site (paratope) thereof, a hybridoma cell line producing the autoantibody, a polypeptide having an amino acid sequence of an antigenic determinant (epitope) specifically binding to the autoantibody, a composition for diagnosing liver cancer including an agent measuring an expression level of the autoantibody or the fragment including the antigen-binding site thereof, a kit for diagnosing liver cancer including the composition, and a method of providing information for diagnosis of liver cancer by using the composition. Further, provided is a method of screening for a therapeutic agent for liver cancer by using an expression level of the autoantibody.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: October 20, 2020
    Assignees: PROTEOMETECH INC., KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Eun Wie Cho, Chang Kyu Heo, Hai Min Hwang, Jeong Heon Ko, Kook Jin Lim, Hye Jung Lee
  • Patent number: 10793915
    Abstract: The present disclosure provides diagnostic methods that are relevant to various cancers and which comprise improvements on a BH3 profiling diagnostic method.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: October 6, 2020
    Assignee: Eutropics Pharmaceuticals, Inc.
    Inventors: Elisha J. Dettman, Michael H. Cardone
  • Patent number: 10787635
    Abstract: A method for expanding circulating tumor cell in vitro includes preparing a cell culture tool having a multi-particle colloidal crystal layer, preparing a cell solution including circulating tumor cells, and contacting the cell solution with the multi-particle colloidal crystal layer, to attach the circulating tumor cells in the cell solution to the multi-particle colloidal crystal layer and rapidly expand by 20 times or more. The multi-particle colloidal crystal layer at least includes first particles having a particle size of 1000 to 5000 nm and second particles having a particle size of 20 to 400 nm. The culture medium in the cell solution at least includes a platelet lysate.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: September 29, 2020
    Assignee: Taipei Medical University
    Inventors: Peng-Yuan Wang, Yin-Ju Chen, Long-Sheng Lu, Thierry Burnouf
  • Patent number: 10782302
    Abstract: Polypeptide marker antigens for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, each of the polypeptide marker antigens binding specifically to at least one autoantibody marker. An antibody binding assay for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, and methods for performing the assay. Methods for determining ovarian cancer recurrence in an ovarian cancer patient. A method for isolating antibodies specific for ovarian cancer by their affinity to the polypeptide marker antigens, and antibodies isolated by that method.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: September 22, 2020
    Assignee: Wayne State University
    Inventors: Michael Tainsky, Madhumita Chatterjee, Gregory Dyson, Nancy Levin
  • Patent number: 10782296
    Abstract: This invention provides an anti-REIC antibody that specifically recognizes a cancer-associated protein (REIC/Dkk-3) and enables monitoring of cancer treatment effects involving the use of the REIC/Dkk-3 gene or the REIC/Dkk-3 protein as a medicine. This invention also provides a method of diagnosis involving the use of such antibody.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: September 22, 2020
    Assignees: National University Corporation Okayama University, Momotaro-Gene Inc.
    Inventors: Hiromi Kumon, Rie Kinoshita, Junichiro Futami
  • Patent number: 10765742
    Abstract: It has now been discovered that activated lymphocyte cell adhesion molecule (ALCAM)—also known as CD166—is the ligand of the innate immune receptor ILT3 that is expressed by DC and monocytes. It has been further discovered that the specific binding of ILT3 to its ligand CD166 on the surface of CD166-expressing cancer cells, arrested cancer cell growth and initiated apoptosis. Therefore, certain embodiments relate to methods and compositions for treating CD166-expressing cancers by administering ILT3Fc, full-length ILT3 or any CD166 ligand-binding fragment thereof.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: September 8, 2020
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Nicole Suciu-Foca, George Vlad, Zheng Xu
  • Patent number: 10751356
    Abstract: Compositions and methods useful for the treatment of cancer, particularly lymphoma, are disclosed.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: August 25, 2020
    Assignee: The Children's Hospital of Philadelphia
    Inventors: Andrei Thomas-Tikhonenko, Elena Sotillo-Pineiro
  • Patent number: 10753936
    Abstract: A method of diagnosing pancreatic cancer in a patient by detecting a level of one or more glycoforms of a Lewis antigen and a level of the one or more glycoforms of MUC5AC. The patient diagnosed with pancreatic cancer then may be treated for this disease. Also, a method for detecting a level of a glycan in a sample which includes using a capture reagent to immobilize the glycan on a substrate; exposing the immobilized glycan to a detection reagent; detecting the level of the immobilized glycan; and combining the biological sample with one or more pre-capture enzymes and/or exposing the immobilized glycan to one or more pre-detection enzymes.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: August 25, 2020
    Assignee: VAN ANDEL RESEARCH INSTITUTE
    Inventors: Brian B. Haab, Bryan Reatini
  • Patent number: 10753937
    Abstract: The present disclosure relates to IGF-IR (insulin like growth factor receptor-1) antibodies characterized by CDR sequences a, to be used in detection methods of IGF-IR expressing tumoral cells.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: August 25, 2020
    Assignee: Pierre Fabre Medicament
    Inventor: Alexandra Jouhanneaud
  • Patent number: 10743768
    Abstract: In certain embodiments, the invention relates to systems and methods for in vivo tomographic imaging of fluorescent probes and/or bioluminescent reporters, wherein a fluorescent probe and a bioluminescent reporter are spatially co-localized (e.g., located at distances equivalent to or smaller than the scattering mean free path of light) in a diffusive medium (e.g., biological tissue). Measurements obtained from bioluminescent and fluorescent modalities are combined per methods described herein.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: August 18, 2020
    Assignee: VisEn Medical, Inc.
    Inventors: Wael Yared, Joshua Kempner, Jorge Ripoll Lorenzo, Alicia Arranz
  • Patent number: 10745694
    Abstract: The present disclosure provides a HTP microbial genomic engineering platform that is computationally driven and integrates molecular biology, automation, and advanced machine learning protocols. This integrative platform utilizes a suite of HTP molecular tool sets to create HTP genetic design libraries, which are derived from, inter alia, scientific insight and iterative pattern recognition. The HTP genomic engineering platform described herein is microbial strain host agnostic and therefore can be implemented across taxa. Furthermore, the disclosed platform can be implemented to modulate or improve any microbial host parameter of interest.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: August 18, 2020
    Assignee: Zymergen Inc.
    Inventors: Zach Serber, Erik Jedediah Dean, Shawn Manchester, Katherine Gora, Michael Flashman, Erin Shellman, Aaron Kimball, Shawn Szyjka, Barbara Frewen, Thomas Treynor, Kenneth S. Bruno
  • Patent number: 10739336
    Abstract: The present invention discloses a magnetic platform for direct and multiplex immune-based detection of trace amount of protein biomarkers for cancers, neurodegenerative disease such as Alzheimer's disease
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: August 11, 2020
    Assignee: Hong Kong Baptist University
    Inventors: See Lok Ho, Hei Nga Chan, Di Xu, Hung Wing Li, Ricky Man Shing Wong
  • Patent number: 10732184
    Abstract: The present invention relates to a method for diagnosis of a cancer, comprising the steps of (i) determining the level of antibodies against protease-activated receptor 1 (PAR1) in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without ovarian cancer; wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative for ovarian cancer in the subject. Furthermore the invention relates to differential diagnosis of cancer and the prediction of the response of a subject to be treated for cancer with a drug.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: August 4, 2020
    Assignee: CellTrend GmbH
    Inventors: Harald Heidecke, Kai Schulze-Forster
  • Patent number: 10733784
    Abstract: Some embodiments include an apparatus for processing radio frequency multiplexed cell images such as single-cell images, for example radio frequency multiplexed excitation (FIRE) images. The images can be from a particle analyzer, such as a flow and scanning cytometer or a laser scanning microscope. Some embodiments include an apparatus for displaying radio frequency multiplexed cell images such as FIRE images.
    Type: Grant
    Filed: April 25, 2019
    Date of Patent: August 4, 2020
    Assignee: BECTON, DICKINSON AND COMPANY
    Inventor: Christopher J. Wolf
  • Patent number: 10723804
    Abstract: The invention relates to an isolated antigenic polypeptide comprising an epitope for binding an MCM2 monoclonal antibody, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of: (a) the amino acid as shown in FIG. 1; and (b) the amino acid sequence wherein said sequence is a variant polypeptide modified by addition, deletion or substitution of at least one amino acid residue as represented in FIG. 1.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: July 28, 2020
    Inventor: Sushant Dhanvijay
  • Patent number: 10718777
    Abstract: The present invention relates to methods of visualizing targets in histological samples, e.g. biopsy samples, wherein the methods comprise staining of the sample with (i) one or more target specific immunochemical stains, and (ii) a histological stain for specific tissue components e.g. iron, mucins glycogen, amyloid, nucleic acids, etc., e.g. hematoxilyn and/or eosin stains or the like, that is used to enhance contrast in the microscopic image of a tissue sample, highlight morphologic structures in the sample for viewing, define and examine tissues, cell populations, or organelles within individual cells. Methods may further comprise evaluation of expression of one or more targets in the sample. The disclosed methods are useful for medical diagnostics.
    Type: Grant
    Filed: December 6, 2011
    Date of Patent: July 21, 2020
    Assignee: AGILENT TECHNOLOGIES, INC.
    Inventor: Jesper Lohse
  • Patent number: 10711068
    Abstract: Anti-CD133 monoclonal antibodies having advantageous properties; products, compositions and kits comprising the monoclonal antibodies; methods (processes) of making the monoclonal antibodies and related compositions, as well as methods of using the monoclonal antibodies in analytical, diagnostic and therapeutic applications.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: July 14, 2020
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Thomas D. Pfister, Robert J. Kinders, Tony Navas
  • Patent number: 10697972
    Abstract: A method of detecting tumor cells in a sample containing cells. In the method, a sample is encapsulated to produce a capsule with the sample encapsulated therein. The capsule containing the sample encapsulated therein is incubated under cell culture conditions suitable for supporting cell activity and growth of tumor cells and the encapsulated sample from the incubated capsule is contacted with a conditionally active antibody that has a higher binding affinity to a cell surface protein of a tumor cell under a first value of a condition of a tumor microenvironment, in comparison with the binding affinity of the conditionally active antibody to the same cell surface protein under a second value of the condition.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: June 30, 2020
    Assignee: BioAtla, LLC
    Inventor: Jay M. Short
  • Patent number: 10690611
    Abstract: A sensor device (30) includes an oscillation unit formed in a semiconductor integrated circuit (40) and having an oscillation frequency which changes in accordance with a physical property of an analyte which comes into contact with the oscillation unit; an oscillation frequency detection unit configured to detect the oscillation frequency, and one or more electrode pairs (36) configured to move a specific analyte dispersed in liquid to an arbitrary location.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: June 23, 2020
    Assignee: SHARP KABUSHIKI KAISHA
    Inventors: Akira Saito, Daiki Sato, Takeshi Mitsunaka, Kunihiko Iizuka
  • Patent number: 10685737
    Abstract: Combination therapies are automatically discovered that provide statistically significantly greater protection against a specific outcome, compared to therapies with fewer treatments. A dataset is received that associates each of a plurality of respective individual treatments with a corresponding outcome and a corresponding set of confounding factors. A plurality of new potential combination therapies are combined iteratively. The received dataset is used to automatically identify at least one candidate combination therapy of the new potential combination therapies that provides a statistically significantly greater protection against an outcome with reference to each of the plurality of respective individual treatments.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: June 16, 2020
    Assignee: International Business Machines Corporation
    Inventors: Gang Hu, Xiang Li, Haifeng Liu, Guo Tong Xie, Ping Zhang
  • Patent number: 10677801
    Abstract: The present invention relates to compositions and methods for-determining a treatment course of action. In particular, the present invention relates to compositions and methods for the prediction of a subject's response to cancer therapies and administration of appropriate treatments.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: June 9, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventor: Daniel Hayes
  • Patent number: 10668093
    Abstract: The present invention relates to a method for treating a cancer with the combination of a topoisomerase II inhibitor (TOP2 inhibitor) and a histone deacetylation inhibitor (HDACi), provides synergistic cancer cell-killing effects, and prolonged overall survival, especially when the expression of checkpoint kinase 1 (CHK-1) is low.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: June 2, 2020
    Assignee: National Yang-Ming University
    Inventor: Jin-Hwang Liu
  • Patent number: 10656058
    Abstract: The present invention relates to a material for aggregating blood cells, used in the preparation of a paraffin block for diagnosing circulating tumor cells (CTCs), and a method for preparing a paraffin block using the same, and more specifically, to a method for detecting CTCs present in the blood through blood sample collection in the preparation of a paraffin block from CTCs, which are present in a very small amount in the blood. The present invention is non-invasive and simple, and thus is very useful for the diagnosis of cancer recurrence and metastatic cancer and for prognosis prediction, and can be a remarkable breakthrough in cancer treatment through the analysis of the onset, metastasis and recurrence mechanisms of cancer.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: May 19, 2020
    Assignee: NATIONAL CANCER CENTER
    Inventors: Hee Jin Chang, Sun Young Kim, Ji Yeon Baek, Hyun Yang Yeo
  • Patent number: 10656073
    Abstract: Methods of optically marking and sorting adherent cells are provided. The methods include providing a plurality of adherent cells attached to a substrate, each adherent cell of the plurality of adherent cells having an optical marker. The methods also include selectively applying light energy to a subset of the plurality of adherent cells, and detaching the plurality of adherent cells from the substrate. These methods also provide the sorting of the plurality of adherent cells.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: May 19, 2020
    Assignee: University of Washington
    Inventors: Daniel T. Chiu, Chun-Ting Kuo, Jiangbo Yu
  • Patent number: 10641767
    Abstract: The invention relates to compositions and methods for the immunoassay of an analyte of interest. The analyte is detected in an immunoassay using three or more antibodies, where in each antibody specifically binds to a different epitope on the analyte. When the analyte of interest in a clinical marker for an acute disease, the detection of the analyte by immunoassay is a diagnosis of the occurrence of the disease.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: May 5, 2020
    Assignee: Abbott Point of Care Inc.
    Inventors: John Lewis Emerson Campbell, Pamela Anne Frank, Meghan Elizabeth Hawkes, Shannon Reishma Lobin, Cary James Miller, Zhen Yang
  • Patent number: 10613090
    Abstract: The present disclosure is directed toward methods and kits for detecting cancer, and in particular breast cancer, in a subject by measuring the levels of at least one of the identified markers, as compared to a control. The expression of the markers in Table 2A is increased in samples from subjects with cancer as compared to the expression level in subjects without cancer and the expression of the markers in Table 2B are decreased in samples from subjects with cancer as compared to the expression level in subjects without cancer. The sample may be lacrimal secretions or eye wash fluid, saliva, or other biological fluids. The kits may include an eye wash kit, collection tubes and protease inhibitors, or protein stabilizers.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: April 7, 2020
    Assignee: Ascendant Diagnostics, LLC
    Inventors: Anna Daily, Lindsay Rutherford
  • Patent number: 10610125
    Abstract: Methods of treating and evaluating subjects having neoactive mutants are described herein.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: April 7, 2020
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Lenny Dang, Valeria Fantin, Stefan Gross, Hyun Gyung Jang, Shengfang Jin, Francesco G. Salituro, Jeffrey O. Saunders, Shin-San Michael Su, Katharine Yen
  • Patent number: 10577439
    Abstract: Some embodiments described herein relate to new polymer coatings for surface functionalization and new processes for grafting pre-grafted DNA-copolymers to surface(s) of substrates for use in DNA sequencing and other diagnostic applications.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: March 3, 2020
    Assignee: Illumina Cambridge Limited
    Inventors: Andrew A. Brown, Wayne N. George, Alexandre Richez, Anne-Cecile Dingwall, Xavier von Hatten
  • Patent number: 10576102
    Abstract: The present invention provides KOC1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: March 3, 2020
    Assignee: ONCOTHERAPY SCIENCE, INC.
    Inventors: Takuya Tsunoda, Ryuji Osawa, Sachiko Yamashita, Tomohisa Watanabe, Tetsuro Hikichi
  • Patent number: 10564167
    Abstract: The present invention relates to methods for detecting the chromatin state of a cell based on recording a super resolution image of nucleosome organization and correlating said imaged with size of nucleosomal clutches, nucleosomal density and/or number of nucleosomes per nucleosomal clutches. Additionally, the invention relates to a kit comprising a first antibody capable of specifically binding to a histone protein and a photoswitchable fluorophore linked-secondary antibody and the use of the kit of the invention for detecting the chromatin state of a cell and isolating a cell in an open chromatin state or in a closed chromatin state. The invention also relates to a device adapted to detect the chromatin state of a cell.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: February 18, 2020
    Assignees: FUNDACIÓ INSTITUT DE CIÈNCIES FOTÓNEQUES, FUNDACIÓ CENTRE DE REGULACIÓ GENÒMICA, INSTITUCIÓ CATALANA DE RECERCA↑ESTUDIS AVANçATS
    Inventors: Melike Lakadamyali, Carlo Manzo, Maria Aurelia Ricci, Maria Pia Cosma
  • Patent number: 10537641
    Abstract: The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2. The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: January 21, 2020
    Assignee: The USA as represented by the Secretary, Department of Health and Human Services
    Inventors: Hisataka Kobayashi, Peter Choyke
  • Patent number: 10527624
    Abstract: The present invention describes a method for detecting castration-resistant prostate cancer (CRPC) in a patient afflicted with prostate cancer comprising (a) performing a direct analysis comprising immunofluorescent staining and morphological characterization of nucleated cells in a blood sample obtained from the patient to detect circulating tumor cells (CTC), (b) determining prevalence of a CTC subpopulation associated with CRPC comprising detecting a measurable feature of each biomarker in a panel of morphological and protein biomarkers, and (c) comparing the prevalence of said CTC subpopulation to a predetermined threshold value, wherein the prevalence of the CTC subpopulation associated with CRPC above said predetermined threshold value is indicative of CRPC. In some embodiments, the CTC subpopulation associated with CRPC comprises CK? CTCs. In some embodiments, the CTC subpopulation associated with CRPC comprises small CTCs.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: January 7, 2020
    Assignee: Epic Sciences, Inc.
    Inventor: Ryan Dittamore